- Home
- ATAI
as 02-21-2025 4:00pm EST
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
| Founded: | 2018 | Country: | Germany |
| Employees: | N/A | City: | BERLIN |
| Market Cap: | 280.2M | IPO Year: | 2021 |
| Target Price: | $9.00 | AVG Volume (30 days): | 4.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $2.85 | Next Earning Date: | 03-27-2025 |
| Revenue: | $331,000 | Revenue Growth: | -0.90% |
| Revenue Growth (this year): | 80.07% | Revenue Growth (next year): | -54.90% |
Stock Insider Trading Activity of ATAI Life Sciences N.V. (ATAI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Apeiron Investment Group Ltd. | ATAI | 10% Owner | Feb 14 '25 | Buy | $2.10 | 10,835,718 | $22,755,007.80 | 40,555,215 |
Latest ATAI Life Sciences N.V. News
ATAI Breaking Stock News: Dive into ATAI Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
GlobeNewswire
10 days ago
atai Life Sciences Announces Pricing of Public Offering of Common Shares
GlobeNewswire
10 days ago
atai Life Sciences Announces Proposed Public Offering of Common Shares
Market Exclusive
19 days ago
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Simply Wall St.
22 days ago
Atai Life Sciences And 2 Other Promising Penny Stocks On US Exchanges
GlobeNewswire
25 days ago
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
Market Exclusive
a month ago
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
GlobeNewswire
a month ago
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
Compare ATAI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATAI ATAI Life Sciences N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.